| # | Drug | Count |
|---|---|---|
| 0 | OCRELIZUMAB | 262 |
| 1 | RITUXIMAB | 96 |
| 2 | HYDROCORTISONE | 45 |
| 3 | PANTOPRAZOLE | 44 |
| 4 | BACLOFEN | 38 |
| 5 | IBUPFROFEN | 37 |
| 6 | IBUPROFEN | 37 |
| 7 | IBUPROFEN 200 MG | 37 |
| 8 | IBUPROFEN 200MG | 37 |
| 9 | IBUPROFEN CAPSULE | 37 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FRANKINCENSE | 2 | 0.0328 |
| 1 | OCRELIZUMAB | 262 | 0.0042 |
| 2 | ESTRIOL | 7 | 0.0038 |
| 3 | BETHANECHOL CHLORIDE | 1 | 0.0018 |
| 4 | PYRIDOSTIGMINE BROMIDE ORAL | 3 | 0.0008 |
| 5 | FINGOLIMOD HYDROCHLORIDE | 3 | 0.0006 |
| 6 | TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05% | 13 | 0.0005 |
| 7 | HYDROCORTISONE | 45 | 0.0005 |
| 8 | DRONABINOL | 4 | 0.0005 |
| 9 | TIZANIDINE HYDROCHLORIDE | 9 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 362 |
| 1 | Corticosteroid [EPC] | 105 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 62 |
| 3 | gamma-Aminobutyric Acid-ergic Agonist [EPC] | 38 |
| 4 | Potassium Channel Blocker [EPC] | 33 |
| 5 | Provitamin D2 Compound [EPC] | 28 |
| 6 | Kinase Inhibitor [EPC] | 26 |
| 7 | Vitamin B12 [EPC] | 24 |
| 8 | Vitamin C [EPC] | 24 |
| 9 | Vitamin D [EPC] | 23 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 362 | 0.0011 |
| 1 | Provitamin D2 Compound [EPC] | 28 | 0.0009 |
| 2 | Cannabinoid [EPC] | 4 | 0.0005 |
| 3 | Potassium Channel Blocker [EPC] | 33 | 0.0005 |
| 4 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 6 | 0.0005 |
| 5 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 6 | 0.0004 |
| 6 | gamma-Aminobutyric Acid-ergic Agonist [EPC] | 38 | 0.0004 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 9 | 0.0004 |
| 8 | Nitrofuran Antibacterial [EPC] | 6 | 0.0003 |
| 9 | Human Immunoglobulin G [EPC] | 7 | 0.0003 |